Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
A recently proposed therapeutic approach for lysosomal storage disorders (LSDs) relies upon the ability of transcription factor EB (TFEB) to stimulate autophagy and induce lysosomal exocytosis leading to cellular clearance. This approach is particularly attractive in glycogen storage disease type II [a severe metabolic myopathy, Pompe disease (PD)] as the currently available therapy, replacement of the missing enzyme acid alpha-glucosidase, fails to reverse skeletal muscle pathology. PD, a paradigm for LSDs, is characterized by both lysosomal abnormality and dysfunctional autophagy. Here, we show that TFEB is a viable therapeutic target in PD: overexpression of TFEB in a new muscle cell culture system and in mouse models of the disease reduced glycogen load and lysosomal size, improved autophagosome processing, and alleviated excessive accumulation of autophagic vacuoles. Unexpectedly, the exocytosed vesicles were labelled with lysosomal and autophagosomal membrane markers, suggesting that TFEB induces exocytosis of autophagolysosomes. Furthermore, the effects of TFEB were almost abrogated in the setting of genetically suppressed autophagy, supporting the role of autophagy in TFEB-mediated cellular clearance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“strategies based on the enhancement of cellular waste disposal capacity (i.e., TFEB‐TFE3 gene therapy) hold promise of preclinical benefits in these pathological scenarios (Spampanato et al, 2013; Bajaj et al, 2019).”
From Autophagy in major human diseases (2021) · cites this paper as Spampanato et al, 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing.
Kabeya, Y., Mizushima, N., Ueno, T., Yamamoto, A., Kirisako, T., Noda, T., Kominami, E., Ohsumi, Y., & Yoshimori, T. (2000) · The EMBO Journal · doi:10.1093/emboj/19.21.5720 · Cited by 6,605 · cited 2×
“…abnormality in PD muscle fibres – autophagic accumulation (Raben et al, 2012) – was not reproduced in PD myotubes, as demonstrated by immunostaining and western analysis with LC3 [a highly specific autophagosomal marker (Kabeya et al, 2000)] (shown for western blot in Supporting Information Fig S1C).”
Cui, C., Cui, J., Jin, F., Cui, Y., Li, R., Jiang, X., Tian, Y., Wang, K., Jiang, P., & Gao, J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479571 · Cited by 5,203
TFEB Links Autophagy to Lysosomal Biogenesis
Settembre, C., Di Malta, C., Polito, V. A., Arencibia, M. G., Vetrini, F., Erdin, S., Erdin, S. U., Huynh, T., Medina, D., Colella, P., et al. (2011) · Science · doi:10.1126/science.1204592 · Cited by 3,365 · cited 5×
“Furthermore, since TFEB has been shown to promote lysosomal– autophagosomal fusion (Settembre & Ballabio, 2011; Settembre et al, 2011), this approach, unlike most current efforts, has the potential to prevent or resolve autophagic build-up.”
InfluentialSelf-citationA Gene Network Regulating Lysosomal Biogenesis and Function
Sardiello, M., Palmieri, M., di Ronza, A., Medina, D. L., Valenza, M., Gennarino, V. A., Di Malta, C., Donaudy, F., Embrione, V., Polishchuk, R. S., et al. (2009) · Science · doi:10.1126/science.1174447 · Cited by 2,543 · cited 5×
“Plasmids: plasmid containing the full-length 3xFlag-tagged human TFEB (referred to as Flag-TFEB) was described previously (Sardiello et al, 2009); plasmid containing the full-length rat LAMP1 (mCherry-LAMP1) was obtained from Dr. Kristien Zaal (Light Imaging Section, Office of Science & Technology,…”
InfluentialSelf-citationMammalian autophagy: core molecular machinery and signaling regulation
Yang, Z., & Klionsky, D. J. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.11.014 · Cited by 1,956 · cited 1×
“Defects in autophagy, a major lysosome-dependent degradative system (Yang & Klionsky, 2010)], significantly contribute to the pathophysiology of several lysosomal storage diseases (Cao et al, 2006; Cox & Cachon-Gonzalez, 2012; Fukuda et al, 2006a,b; Liao et al, 2007; Lieberman et al, 2012; Settembre…”
A lysosome‐to‐nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB
Settembre, C., Zoncu, R., Medina, D. L., Vetrini, F., Erdin, S., Erdin, S., Huynh, T., Ferron, M., Karsenty, G., Vellard, M. C., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.32 · Cited by 1,920
Self-citationLysosomes: fusion and function
Luzio, J. P., Pryor, P. R., & Bright, N. A. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2217 · Cited by 1,740 · cited 1×
“Lysosomal function depends on the ability of lysosomal membranes to fuse with other vesicles’ membranes and with the plasma membrane (Luzio et al, 2007).”
Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function
Saftig, P., & Klumperman, J. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2745 · Cited by 1,648 · cited 1×
“LAMPs are considered to be of key importance for lysosomal movement, maturation of autophago-somes and lysosomal exocytosis (Saftig & Klumperman, 2009).”
Roczniak-Ferguson, A., Petit, C. S., Froehlich, F., Qian, S., Ky, J., Angarola, B., Walther, T. C., & Ferguson, S. M. (2012) · Science Signaling · doi:10.1126/scisignal.2002790 · Cited by 1,366
MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB
Martina, J. A., Chen, Y., Gucek, M., & Puertollano, R. (2012) · Autophagy · doi:10.4161/auto.19653 · Cited by 1,333 · cited 6×
“Next, we attempted to activate endogenous TFEB by pharmacologically targeting mTORC1, which has been shown to negatively regulate TFEB (Martina et al, 2012; RoczniakFerguson et al, 2012; Settembre et al, 2012).”
BackgroundMethodInfluentialSelf-citation
Cited by
The role of autophagy in neurodegenerative disease
Nixon, R. A. (2013) · Nature Medicine · doi:10.1038/nm.3232 · Cited by 2,059
Signals from the lysosome: a control centre for cellular clearance and energy metabolism
Settembre, C., Fraldi, A., Medina, D. L., & Ballabio, A. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3565 · Cited by 1,697
Self-citationAutophagy in major human diseases
Klionsky, D. J., Petroni, G., Amaravadi, R. K., Baehrecke, E. H., Ballabio, A., Boya, P., Bravo‐San Pedro, J. M., Cadwell, K., Cecconi, F., Choi, A. M. K., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021108863 · Cited by 1,585
Self-citationLysosomes as dynamic regulators of cell and organismal homeostasis
Ballabio, A., & Bonifacino, J. S. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0185-4 · Cited by 1,469
Self-citationXu, H., & Ren, D. (2015) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021014-071649 · Cited by 1,034
“Strikingly, the beneficial effects of TFEB on various LSDs depend on TRPML1 and lysosomal exocytosis (49, 133).”
BackgroundAutophagy at the crossroads of catabolism and anabolism
Kaur, J., & Debnath, J. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4024 · Cited by 991
Napolitano, G., & Ballabio, A. (2016) · Journal of Cell Science · doi:10.1242/jcs.146365 · Cited by 845
“…have been shown to be beneficial in reducing substrate accumulation; such overexpression also improved overall autophagy and lysosomal function, and ameliorated the severity of cellular and tissue phenotypes (Medina et al., 2011; Rega et al., 2016; Song et al., 2013; Spampanato et al., 2013).”
BackgroundSelf-citationLysosomal membrane permeabilization and cell death
Wang, F., Gómez‐Sintes, R., & Boya, P. (2018) · Traffic · doi:10.1111/tra.12613 · Cited by 776
“In a mice model for Pompe diseases, expression of TFEB clears the enlarged autolysosomes with undegraded contents.(50) In summary, multiple mechanisms act to maintain lysosomal stability and eliminate compromised lysosomes.”
BackgroundMartina, J. A., Diab, H. I., Lishu, L., Jeong-A, L., Patange, S., Raben, N., & Puertollano, R. (2014) · Science Signaling · doi:10.1126/scisignal.2004754 · Cited by 677
Self-citationThe Lysosome as a Regulatory Hub
Perera, R. M., & Zoncu, R. (2016) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-111315-125125 · Cited by 660
“…overexpression of TFEB was shown to promote autophagosomal-lysosomal fusion, lysosomal trafficking, and exocytosis, leading to a dramatic reduction in intralysosomal content in multiple cellular models of LSDs (Decressac et al. 2013, Medina et al. 2011, Song et al. 2013, Spampanato et al. 2013).”
BackgroundColacurcio, D. J., & Nixon, R. A. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.05.004 · Cited by 548
“It is not known f -syn affects the v-ATPase, but -syn over-expression induces ysosomal de-acidification in vitro (Stefanis et al., 2001) and, in everal mouse models, disrupts lysosomal function (Cuervo et al., 004; Martinez-Vicente et al., 2008; Xilouri et al., 2009).”
BackgroundPuertollano, R., Ferguson, S. M., Brugarolas, J., & Ballabio, A. (2018) · The EMBO Journal · doi:10.15252/embj.201798804 · Cited by 531
“…diseases resulting from the accumulation of unde-graded substances, such as lysosomal storage diseases (LSD; Medina et al , 2011; Song et al , 2013; Spampanato et al , 2013; Rega et al , 2016), Parkinson’s disease (Dehay et al , 2010; Decressac et al , 2013; Kilpatrick et al , 2015), Alzheimer’s…”
Self-citationThe return of the nucleus: transcriptional and epigenetic control of autophagy
Füllgrabe, J., Klionsky, D. J., & Joseph, B. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3716 · Cited by 466
Buratta, S., Tancini, B., Sagini, K., Delo, F., Chiaradia, E., Urbanelli, L., & Emiliani, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072576 · Cited by 446
“Moreover, clearance of stored materials was also obtained in in vivo studies upon viral-mediated TFEB gene transfer in mouse models of multiple sulphatase deficiency [2] and Pompe’s disease [28].”
BackgroundTFEB and TFE3: Linking Lysosomes to Cellular Adaptation to Stress
Raben, N., & Puertollano, R. (2016) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-111315-125407 · Cited by 437
“…cells from a murine model of juvenile form of Neuronal Ceroid lipofuscinosis (Batten disease; mutations in CLN3 gene), and in immortalized muscle cells from a mouse model of Pompe disease (deficiency of glycogen-degrading acid-alpha glucosidase) (Medina et al 2011) (Spampanato et al 2013).”
BackgroundSelf-citationThe Autophagy–Lysosomal Pathway in Neurodegeneration: A TFEB Perspective
Martini-Stoica, H., Xu, Y., Ballabio, A., & Zheng, H. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2016.02.002 · Cited by 436
Self-citationmTOR-dependent phosphorylation controls TFEB nuclear export
Napolitano, G., Esposito, A., Choi, H., Matarese, M., Benedetti, V., Di Malta, C., Monfregola, J., Medina, D. L., Lippincott-Schwartz, J., & Ballabio, A. (2018) · Nature Communications · doi:10.1038/s41467-018-05862-6 · Cited by 406
Self-citationLysosomal storage diseases: from pathophysiology to therapy
Parenti, G., Andria, G., & Ballabio, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-122313-085916 · Cited by 404
Self-citationBrief update on endocytosis of nanomedicines
Patel, S., Kim, J., Herrera, M., Mukherjee, A., Kabanov, A. V., & Sahay, G. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.08.004 · Cited by 400
“transfected GAA null mice with adeno-associated virus (AAV) expressing transcription factor EB (TFEB), a transcription factor that has been shown to be a master regulator of lysosomal biogenesis and autophagy [151,152].”
MethodProtein kinase C controls lysosome biogenesis independently of mTORC1
Li, Y., Xu, M., Ding, X., Yan, C., Song, Z., Chen, L., Huang, X., Wang, X., Jian, Y., Tang, G., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3407 · Cited by 353
“HEP14-biotin (∼0.8 µg) immobilized on streptavidin-agarose beads (20 µl) was then incubated in Hepes buffer with MBP, MBP-PKCα-C1 or MBP-PKCδ-C1 (3 µg of each) with different © Macmillan Publishers Limited .”
MethodInfluentialDevelopment of autophagy inducers in clinical medicine
Levine, B., Packer, M., & Codogno, P. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73938 · Cited by 347
“As a proof of principle, Tfeb gene therapy decreases glycogen storage and excess accumulation of autophagosomes in a murine model of the lysosomal storage disease, Pompe disease (31).”
Innate Host Defense Requires TFEB-Mediated Transcription of Cytoprotective and Antimicrobial Genes
Visvikis, O., Ihuegbu, N., Labed, S. A., Luhachack, L. G., Alves, A.-M. F., Wollenberg, A. C., Stuart, L. M., Stormo, G. D., & Irazoqui, J. E. (2014) · Immunity · doi:10.1016/j.immuni.2014.05.002 · Cited by 335
“Due to its role in stress responses, enhancement of TFEB activity has emerged as a potential therapeutic approach for multiple lysosomal and protein aggregation disorders (Decressac et al., 2013; Pastore et al., 2013; Spampanato et al., 2013).”
BackgroundThe biogenesis of lysosomes and lysosome-related organelles
Luzio, J. P., Hackmann, Y., Dieckmann, N. M. G., & Griffiths, G. M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016840 · Cited by 330
“In some cellular models of lysosomal storage diseases, overexpression of TFEB has been shown to lead to an increase in lysosomal docking and exocytosis, a decrease in lysosomal size, and consequently clearance of accumulated metabolites (Medina et al. 2011; Spampanato et al. 2013).”
BackgroundMiT/TFE transcription factors are activated during mitophagy downstream of Parkin and Atg5
Nezich, C. L., Wang, C., Fogel, A. I., & Youle, R. J. (2015) · Journal of Cell Biology · doi:10.1083/jcb.201501002 · Cited by 309
“…of LSDs and neurodegenerative disorders, including Gaucher disease and Tay-Sachs disease (Song et al., 2013); Pompe disease (Medina et al., 2011; Spampanato et al., 2013); multiple sulfatase deficiency, Batten disease, and mucopolysaccharidosis type IIIA (Medina et al., 2011); Alzheimer’s…”
BackgroundThe lysosome as a command-and-control center for cellular metabolism
Lim, C.-Y., & Zoncu, R. (2016) · Journal of Cell Biology · doi:10.1083/jcb.201607005 · Cited by 295
“Of note, the capability of TFEB to promote cellular clearance could also be exploited to develop novel therapeutics for diseases associated with lysosomal and autophagic dysfunction such as lysosomal storage diseases (Settembre et al., 2013a; Spampanato et al., 2013; Lim et al., 2015) and common neurodegenerative dise…”
BackgroundTan, A., Prasad, R., Lee, C., & Jho, E.-H. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-01028-6 · Cited by 250
“Pompe disease is caused by deficiency of the lysosomal enzyme acid α-glucosidase (GAA; acid maltase), which catabolizes glycogen to glucose in acidic lysosomes.”
BackgroundInfluentialLysosome trafficking and signaling in health and neurodegenerative diseases
Lie, P. P. Y., & Nixon, R. A. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.05.015 · Cited by 269
Autophagy, lipophagy and lysosomal lipid storage disorders
Ward, C., Martinez-Lopez, N., Otten, E. G., Carroll, B., Maetzel, D., Singh, R., Sarkar, S., & Korolchuk, V. I. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.01.006 · Cited by 244
“[175] and associated p62 and ubiquitin inclusions all of which contribute to cellular toxicity [161,176].”
BackgroundTranscriptional Regulation of Autophagy: Mechanisms and Diseases
Di Malta, C., Cinque, L., & Settembre, C. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00114 · Cited by 255
TFEB enhances astroglial uptake of extracellular tau species and reduces tau spreading
Martini-Stoica, H., Cole, A. L., Swartzlander, D. B., Chen, F., Wan, Y.-W., Bajaj, L., Bader, D. A., Lee, V. M. Y., Trojanowski, J. Q., Liu, Z., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20172158 · Cited by 253
“TFEB also promotes clearance of aberrant storage material in lysosomal storage disorders (Medina et al., 2011; Song et al., 2013; Spampanato et al., 2013; Palmieri et al., 2017).”
BackgroundPompe Disease: From Basic Science to Therapy
Kohler, L., Puertollano, R., & Raben, N. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-0655-y · Cited by 234
Self-citationParenti, G., Andria, G., & Valenzano, K. J. (2015) · Molecular Therapy · doi:10.1038/mt.2015.62 · Cited by 230
Self-citationLysosomal storage disorders – challenges, concepts and avenues for therapy: beyond rare diseases
Marques, A. R. A., & Saftig, P. (2019) · Journal of Cell Science · doi:10.1242/jcs.221739 · Cited by 224
“Here, TFEB overexpression in muscle cells (Spampanato et al., 2013) and in a murine model of Pompe disease (Gatto et al.”
BackgroundLysosome: regulator of lipid degradation pathways
Settembre, C., & Ballabio, A. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.06.006 · Cited by 229
Self-citationThe rapidly evolving view of lysosomal storage diseases
Parenti, G., Medina, D. L., & Ballabio, A. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202012836 · Cited by 230
“In vitro and in vivo overexpression of TFEB also induced exocytosis, enhanced glycogen clearance, and resulted in some improvements in physical performance of Pompe disease mice (Spampanato et al, 2013; Gatto et al, 2017).”
BackgroundSelf-citationSong, J.-X., Sun, Y.-R., Peluso, I., Zeng, Y., Yu, X., Lu, J.-H., Xu, Z., Wang, M.-Z., Liu, L.-F., Huang, Y.-Y., et al. (2016) · Autophagy · doi:10.1080/15548627.2016.1179404 · Cited by 223
Self-citationPompe disease: from pathophysiology to therapy and back again
Lim, J.-A., Li, L., & Raben, N. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00177 · Cited by 207
“The in vitro model replicates lysosomal, but not autophagic pathology (see below) (Figure 1; Spampanato et al., 2013), and as such can be used to decipher the early events which precede the development of autophagic buildup—a hallmark of the disease in Pompe muscle fibers.”
BackgroundInfluentialSelf-citationSTUB1 regulates TFEB‐induced autophagy–lysosome pathway
Sha, Y., Rao, L., Settembre, C., Ballabio, A., & Eissa, N. T. (2017) · The EMBO Journal · doi:10.15252/embj.201796699 · Cited by 224
“(Medina et al , 2011; Song et al , 2013; Spampanato et al , 2013).”
Self-citationORF3a of SARS-CoV-2 promotes lysosomal exocytosis-mediated viral egress
Chen, D., Zheng, Q., Sun, L., Ji, M., Li, Y., Deng, H., & Zhang, H. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.10.006 · Cited by 201
Structure of the lysosomal mTORC1–TFEB–Rag–Ragulator megacomplex
Cui, Z., Napolitano, G., de Araujo, M. E. G., Esposito, A., Monfregola, J., Huber, L. A., Ballabio, A., & Hurley, J. H. (2023) · Nature · doi:10.1038/s41586-022-05652-7 · Cited by 191
Self-citationde Araujo, M. E. G., Liebscher, G., Hess, M. W., & Huber, L. A. (2020) · Traffic · doi:10.1111/tra.12714 · Cited by 203
The role of TRPMLs in endolysosomal trafficking and function
Venkatachalam, K., Wong, C.-O., & Zhu, M. X. (2015) · Cell Calcium · doi:10.1016/j.ceca.2014.10.008 · Cited by 204
Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis
Mole, S. E., Anderson, G., Band, H. A., Berkovic, S. F., Cooper, J. D., Kleine Holthaus, S.-M., McKay, T. R., Medina, D. L., Rahim, A. A., Schulz, A., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30368-5 · Cited by 206
Transcriptional regulation of mammalian autophagy at a glance
Füllgrabe, J., Ghislat, G., Cho, D.-H., & Rubinsztein, D. C. (2016) · Journal of Cell Science · doi:10.1242/jcs.188920 · Cited by 198
“Moreover, activation of autophagy and lysosomal activity by TFEB attenuates the pathological phenotype in mouse models of Pompe disease (Spampanato et al., 2013).”
BackgroundThe Parkinson’s disease-associated genes ATP13A2 and SYT11 regulate autophagy via a common pathway
Bento, C. F., Ashkenazi, A., Jimenez-Sanchez, M., & Rubinsztein, D. C. (2016) · Nature Communications · doi:10.1038/ncomms11803 · Cited by 193
TDP‐43 loss of function increases TFEB activity and blocks autophagosome–lysosome fusion
Xia, Q., Wang, H., Hao, Z., Fu, C., Hu, Q., Gao, F., Ren, H., Chen, D., Han, J., Ying, Z., et al. (2016) · The EMBO Journal · doi:10.15252/embj.201591998 · Cited by 195
“…and that TFEB is a master regulator of ALP and is functionally associated with neurodegenerative diseases as recently reported (Sardiello et al , 2009; Settembre et al , 2011; Tsunemi et al , 2012; Decressac et al , 2013; Spampanato et al , 2013), we wonder whether TDP-43 is able to regulate TFEB.”
Lysosomal exocytosis and lipid storage disorders
Samie, M. A., & Xu, H. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r046896 · Cited by 189
Martinez-Lopez, N., Athonvarangkul, D., & Singh, R. (2015) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4939-2404-2_3 · Cited by 180
“Similarly, overexpression of TFEB alleviates glycogen buildup in muscles as a result of Pompe disease [68], a severe form of metabolic myopathy occurring as a consequence of an absence of acid α-glucosidase.”
BackgroundRole of exosomes in the protection of cellular homeostasis
Desdín-Micó, G., & Mittelbrunn, M. (2017) · Cell Adhesion & Migration · doi:10.1080/19336918.2016.1251000 · Cited by 174
“storage diseases, cells can defend themselves against proteotoxicity releasing dysfunctional lysosomes.(78,79) Other”
BackgroundDysregulation of autophagy as a common mechanism in lysosomal storage diseases
Seranova, E., Connolly, K. J., Zatyka, M., Rosenstock, T. R., Barrett, T., Tuxworth, R. I., & Sarkar, S. (2017) · Essays in Biochemistry · doi:10.1042/ebc20170055 · Cited by 176
Misregulation of autophagy and protein degradation systems in myopathies and muscular dystrophies.
Sandri, M., Coletto, L., Grumati, P., & Bonaldo, P. (2013) · Journal of Cell Science · doi:10.1242/jcs.114041 · Cited by 179
“These findings indicate that modulation of TFEB activity might be a promising target for the development of a better therapy for Pompe disease (Spampanato et al., 2013).”
BackgroundInfluentialPeric, A., & Annaert, W. (2015) · Acta Neuropathologica · doi:10.1007/s00401-014-1379-7 · Cited by 161
“As its efficacy has already been demonstrated in several diseases, including lysosomal storage disorders [137], Huntington’s disease (HD) [152] and Parkinson’s disease (PD) [29], it is expected that similar benefits may also be achieved in the AD context.”
BackgroundCongenital disorders of autophagy: an emerging novel class of inborn errors of neuro-metabolism
Ebrahimi-Fakhari, D., Saffari, A., Wahlster, L., Lu, J., Byrne, S., Hoffmann, G. F., Jungbluth, H., & Sahin, M. (2016) · Brain · doi:10.1093/brain/awv371 · Cited by 158
Solomon, M. A., & Muro, S. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.004 · Cited by 170
“been documented in Batten disease, MPS IIIA, Pompe disease, and others [110,111].”
Martina, J. A., Diab, H. I., Li, H., & Puertollano, R. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1565-8 · Cited by 158
“Overexpression of TFEB also decreased intra-lysosomal accumulation of lipofuscin in fibroblasts derived from a patient with Batten disease [101] and dramatically reduced lysosomal size and intra-lysosomal glycogen accumulation in Pompe disease myotubes [102], thus suggesting that TFEB promotes clearance of different t…”
Self-citationLysosomal adaptation: How cells respond to lysosomotropic compounds
Lu, S., Sung, T., Lin, N., Abraham, R. T., & Jessen, B. A. (2017) · PLOS ONE · doi:10.1371/journal.pone.0173771 · Cited by 152
Lysosome biogenesis in health and disease
Bajaj, L., Lotfi, P., Pal, R., Ronza, A. D., Sharma, J., & Sardiello, M. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14564 · Cited by 153
“AAV-mediated TFEB over-expression in the muscle of a mouse model of Pompe disease reduced abnormal glycogen storage and alleviated the autophagic buildup (Spampanato et al. 2013).”
BackgroundResultGray, M. A., Choy, C. H., Dayam, R. M., Ospina-Escobar, E., Somerville, A., Xiao, X., Ferguson, S. M., & Botelho, R. J. (2016) · Current Biology · doi:10.1016/j.cub.2016.05.070 · Cited by 156
Chandra, S., Roy, A., Jana, M., & Pahan, K. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.12.007 · Cited by 149
MitophAging: Mitophagy in Aging and Disease
Bakula, D., & Scheibye-Knudsen, M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00239 · Cited by 148
Puertollano, R. (2014) · F1000Prime Reports · doi:10.12703/p6-52 · Cited by 142
“mediated lysosomal exocytosis is significantly reduced in autophagy-defective cells [32].”
BackgroundSelf-citationIntracellular sphingosine releases calcium from lysosomes
Höglinger, D., Haberkant, P., Aguilera-Romero, A., Riezman, H., Porter, F. D., Platt, F. M., Galione, A., & Schultz, C. (2015) · eLife · doi:10.7554/elife.10616 · Cited by 159
Lysosomal Exocytosis: The Extracellular Role of an Intracellular Organelle
Tancini, B., Buratta, S., Delo, F., Sagini, K., Chiaradia, E., Pellegrino, R. M., Emiliani, C., & Urbanelli, L. (2020) · Membranes · doi:10.3390/membranes10120406 · Cited by 144
“Similar results were also obtained for glycogenosis type II (Pompe’s disease) [152].”
ResultHow Lysosomes Sense, Integrate, and Cope with Stress
Saftig, P., & Puertollano, R. (2021) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.09.004 · Cited by 133
Self-citationRegulation of lysosomal ion homeostasis by channels and transporters
Xiong, J., & Zhu, M. X. (2016) · Science China Life Sciences · doi:10.1007/s11427-016-5090-x · Cited by 141
“Other studies also showed that upregulating TRPML1 channel function alleviated pathological phenotypes at the cellular level (Spampanato et al., 2013).”
Dasouki, M., Jawdat, O., Almadhoun, O. F., Pasnoor, M., McVey, A., Abuzinadah, A. R., Herbelin, L. L., Barohn, R. J., & Dimachkie, M. M. (2014) · Neurologic Clinics · doi:10.1016/j.ncl.2014.04.010 · Cited by 156
The Role of Autophagy in Skeletal Muscle Diseases
Xia, Q., Huang, X., Huang, J., Zheng, Y., March, M., Li, J., & Wei, Y. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.638983 · Cited by 103
Sardiello, M. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13131 · Cited by 135
Chandra, S., Jana, M., & Pahan, K. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.0054-18.2018 · Cited by 134
“Numerous studies have highlighted the wide applicability and therapeutic potential of TFEB-mediated lysosomal modulation in lysosomal storage diseases (LSDs) such as Gaucher disease, Tay–Sachs disease (Song et al., 2013), Pompe disease (Spampanato et al., 2013), and cystinosis (Rega et al., 2016).”
BackgroundDefects in calcium homeostasis and mitochondria can be reversed in Pompe disease
Lim, J.-A., Li, L., Kakhlon, O., Myerowitz, R., & Raben, N. (2015) · Autophagy · doi:10.1080/15548627.2015.1009779 · Cited by 122
Self-citationExercise activates lysosomal function in the brain through AMPK‐SIRT1‐TFEB pathway
Huang, J., Wang, X., Zhu, Y., Li, Z., Zhu, Y., Wu, J., Qin, Z., Xiang, M., & Lin, F. (2019) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13114 · Cited by 129
Autophagy–lysosomal-associated neuronal death in neurodegenerative disease
Nixon, R. A. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02799-7 · Cited by 133
“…activities [25, 157] by genetic manipulation of lysosomal protease inhibitors [217, 250], increasing lysosomal biogenesis and transcription of vATPase subunits [56, 148, 213], or pharmacologically re-acidifying lysosome, including using lysosomal-targeted acidic nanoparticles [17, 45, 127].”
Lysosomal adaptation: how the lysosome responds to external cues
Settembre, C., & Ballabio, A. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016907 · Cited by 126
“Similar results were obtained in a completely different type of LSD, glycogenosis type II (Pompe disease), which is characterized by the accumulation of glycogen mostly in muscle, heart, and liver leading to progressive muscular and heart dysfunction (Spampanato et al. 2013).”
BackgroundResultSelf-citationEngineered skeletal muscles for disease modeling and drug discovery
Wang, J., Khodabukus, A., Rao, L., Vandusen, K., Abutaleb, N., & Bursac, N. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119416 · Cited by 115
Evidence for lysosomal biogenesis proteome defect and impaired autophagy in preeclampsia
Nakashima, A., Cheng, S., Ikawa, M., Yoshimori, T., Huber, W. J., Menon, R., Huang, Z., Fierce, J., Padbury, J. F., Sadovsky, Y., et al. (2019) · Autophagy · doi:10.1080/15548627.2019.1707494 · Cited by 132
Organelle autoregulation--stress responses in the ER, Golgi, mitochondria and lysosome
Sasaki, K. E., & Yoshida, H. (2015) · The Journal of Biochemistry · doi:10.1093/jb/mvv010 · Cited by 131
Endothelial TFEB (Transcription Factor EB) Positively Regulates Postischemic Angiogenesis
Fan, Y., Lu, H., Liang, W., Garcia-Barrio, M. T., Guo, Y., Zhang, J., Zhu, T., Hao, Y., Zhang, J., & Chen, Y. E. (2018) · Circulation Research · doi:10.1161/circresaha.118.312672 · Cited by 121
Pompe Disease: New Developments in an Old Lysosomal Storage Disorder
Meena, N. K., & Raben, N. (2020) · Biomolecules · doi:10.3390/biom10091339 · Cited by 128
“Likewise, the mechanism of impaired autophagosomal-lysosomal fusion, which can be directly observed by time-lapse microscopy of live fibers co-stained with LC3/LAMP1 [67], is not fully understood.”
BackgroundSelf-citationSettembre, C., & Medina, D. L. (2015) · Methods in cell biology · doi:10.1016/bs.mcb.2014.11.011 · Cited by 123
A Self-Assembled α-Synuclein Nanoscavenger for Parkinson’s Disease
Liu, J., Liu, C., Zhang, J., Zhang, Y., Liu, K., Song, J., Sreenivasmurthy, S. G., Wang, Z., Shi, Y., Chu, C., et al. (2020) · ACS Nano · doi:10.1021/acsnano.9b06453 · Cited by 121
Drosophila Mitf regulates the V-ATPase and the lysosomal-autophagic pathway
Bouché, V., Espinosa, A. P., Leone, L., Sardiello, M., Ballabio, A., & Botas, J. (2016) · Autophagy · doi:10.1080/15548627.2015.1134081 · Cited by 111
Self-citationRegulation of TFEB activity and its potential as a therapeutic target against kidney diseases
Zhang, W., Li, X., Wang, S., Chen, Y., & Liu, H. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-0265-4 · Cited by 119
Deneubourg, C., Ramm, M., Smith, L. J., Baron, O., Singh, K., Byrne, S., Duchen, M. R., Gautel, M., Eskelinen, E., Fanto, M., et al. (2021) · Autophagy · doi:10.1080/15548627.2021.1943177 · Cited by 120
“The accumulation of autophagic debris, glycogen-containing lysosomes as well as exocytosed vesicles observed in those muscle biopsies share common pathological features with the severe metabolic myopathy observed in one of the GSDs, Pompe Disease [84,206].”
BackgroundExercise induces TFEB expression and activity in skeletal muscle in a PGC-1α-dependent manner
Erlich, A. T., Brownlee, D. M., Beyfuss, K., & Hood, D. A. (2018) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00162.2017 · Cited by 110
Neuronal XBP-1 Activates Intestinal Lysosomes to Improve Proteostasis in C. elegans
Imanikia, S., Özbey, N. P., Krueger, C., Casanueva, M. O., & Taylor, R. C. (2019) · Current Biology · doi:10.1016/j.cub.2019.06.031 · Cited by 113
Autophagy in neuronal cells: general principles and physiological and pathological functions
Daμμe, M., Suntio, T., Säftig, P., & Eskelinen, E. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1361-4 · Cited by 119
“TFEB increased lysosome biogenesis and exocytosis of autophagosomes, which both contributed to the removal of the excessive accumulation of autophagic cargo in cells [68, 216].”
Immunometabolic rewiring of tubular epithelial cells in kidney disease
van der Rijt, S., Leemans, J. C., Florquin, S., Houtkooper, R. H., & Tammaro, A. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00592-x · Cited by 110
Activation of the transcription factor EB rescues lysosomal abnormalities in cystinotic kidney cells
Rega, L. R., Polishchuk, E., Montefusco, S., Napolitano, G., Tozzi, G., Zhang, J., Bellomo, F., Taranta, A., Pastore, A., Polishchuk, R., et al. (2016) · Kidney International · doi:10.1016/j.kint.2015.12.045 · Cited by 115
“870 clearance of aberrant aggregates.(21,22,28) In this context, it is important to note that recent advances in the field of cystinosis have highlighted that aberrant autophagy is an important contributor to the pathogenesis of the disease.”
BackgroundSelf-citationModulation of mTOR signaling as a strategy for the treatment of Pompe disease
Lim, J., Li, L., Shirihai, O. S., Trudeau, K. M., Puertollano, R., & Raben, N. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606547 · Cited by 94
“Muscle cell cultures, treatment, processing and analysis The generation of immortalized WT and KO (clones 6 and RF1) mouse muscle cells has been previously described (Spampanato et al, 2013).”
BackgroundMethodInfluentialSelf-citationEffects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons
Magalhaes, J., Gegg, M. E., Migdalska-Richards, A., & Schapira, A. H. (2018) · Scientific Reports · doi:10.1038/s41598-018-19479-8 · Cited by 92
MiT/TFE Family of Transcription Factors: An Evolutionary Perspective
La Spina, M., Contreras, P. S., Rissone, A., Meena, N. K., Jeong, E., & Martina, J. A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.609683 · Cited by 94
Defective lysosome reformation during autophagy causes skeletal muscle disease
McGrath, M. J., Eramo, M. J., Gurung, R., Sriratana, A., Gehrig, S. M., Lynch, G. S., Lourdes, S. R., Köentgen, F., Feeney, S. J., Lazarou, M., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci135124 · Cited by 96
Improved efficacy of a next-generation ERT in murine Pompe disease
Xu, S., Lun, Y., Frascella, M., Garcia, A., Soska, R., Nair, A., Ponery, A. S., Schilling, A. E., Feng, J., Tuske, S. J., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.125358 · Cited by 92
“include genetic suppression of autophagy by inactivation of a key autophagic gene, ATG7; overexpression of transcription factors TFEB and TFE3 to stimulate autophagosomal-lysosomal fusion and lysosomal exocytosis; and inhibition of autophagy by upregulation of mammalian target of rapamycin complex 1 (mTORC1) (46, 79,…”
BackgroundSelf-citationLi, M., Pi, H., Yang, Z., Reiter, R. J., Xu, S., Chen, X., Chen, C., Zhang, L., Yang, M., Li, Y., et al. (2016) · Journal of Pineal Research · doi:10.1111/jpi.12353 · Cited by 92
From the regulatory mechanism of TFEB to its therapeutic implications
Chen, H.-X., Gong, S., Zhang, H., Chen, Y., Liu, Y., Hao, J., Liu, H.-F., & Li, X. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01850-6 · Cited by 90
“In addition to the fi nding that TFEB plays a pathogenic role in several cancers [14, 43, 84], TFEB plays a protective role in most diseases, such as LSDs [13, 85], neurodegenerative diseases [6, 86, 87], ischemic injury [88, 89], metabolic disorders [15, 90], and in fl ammation [17 – 19].”
BackgroundThe ion channels of endomembranes
Hu, M., Feng, X., Liu, Q., Liu, S., Huang, F., & Xu, H. (2024) · Physiological Reviews · doi:10.1152/physrev.00025.2023 · Cited by 91
Vainshtein, A., Grumati, P., Sandri, M., & Bonaldo, P. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1096-z · Cited by 88
“Indeed, overexpression of TFEB, a key transcription factor for lysosome biogenesis, was shown to result in lysosomal fusion with the plasma membrane, and thus in effective lysosomal exocytosis and significant glycogen clearance [68].”
BackgroundMoving towards effective therapeutic strategies for Neuronal Ceroid Lipofuscinosis
Geraets, R. D., Koh, S. Y., Hastings, M. L., Kielian, T., Pearce, D. A., & Weimer, J. M. (2016) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-016-0414-2 · Cited by 90
Lysosomal quality control: molecular mechanisms and therapeutic implications
Yang, H., & Tan, J. X. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.01.001 · Cited by 91
Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies
Arotcarena, M.-L., Bourdenx, M., Dutheil, N., Thiolat, M.-L., Doudnikoff, E., Dovero, S., Ballabio, A., Fernagut, P.-O., Meissner, W. G., Bezard, E., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.129719 · Cited by 84
“TFEB has also been validated as an emerging therapeutic target to enhance lysosomal biogenesis and autophagy in different disorders — such as Alzheimer’s disease, in which its astrocytic expression decreases misfolded Tau spreading (52) — but also for lysosomal storage disorders, such as Pompe Disease (53), as well as…”
Self-citation
Metadata
- Authors
- Spampanato, C., Feeney, E., Li, L., Cardone, M., Lim, J., Annunziata, F., Zare, H., Polishchuk, R., Puertollano, R., Parenti, G., Ballabio, A., & Raben, N.
- Affiliations
- Baylor College of Medicine (US)
- National Institutes of Health (US)
- Telethon Institute Of Genetics And Medicine (IT)
- Federico II University Hospital (IT)
- Corresponding author
- Ballabio, Andrea
- Raben, Nina
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2013-04-18
- Volume
- 5
- Issue
- 5
- Pages
- 691-706
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC3662313
- OpenAlex
- W2113698463
- Cited by
- 341
- References
- 68
- Citations by year
- 2026: 9 · 2025: 20 · 2024: 23 · 2023: 20 · 2022: 24 · 2021: 33 · 2020: 29 · 2019: 37 · 2018: 22 · 2017: 22 · 2016: 35 · 2015: 29 · 2014: 28 · 2013: 10
- FWCI
- 23.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- public-domain
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- March of Dimes Foundation
- Beyond Batten Disease Foundation
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke (R01NS078072)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- FP7 Ideas: European Research Council (250154)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Keywords
- TFEB, Pompe disease, lysosomal storage disease, autophagy, lysosomal exocytosis, acid alpha-glucosidase deficiency, skeletal muscle, therapeutic target, lysosomal dysfunction
- MeSH terms
- Adenoviridae, alpha-Glucosidases, Animals, Autophagy, Cells, Cultured, Disease Models, Animal, Exocytosis, Genetic Vectors, Glycogen, Glycogen Storage Disease Type II, Lysosomes, Mice, Knockout, Muscle, Skeletal, Mice, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.